Amneal FDA Monday, November 2, 2026 +0.20 Positive

FDA Approves CYCLOPHOSPHAMIDE — Amneal Pharmaceuticals LLC

The FDA has approved a new oral formulation of generic Cyclophosphamide by Amneal Pharmaceuticals LLC, providing patients with a generic alternative to injectable options. This approval is expected to significantly reduce costs for cancer treatments and expand access to this essential chemotherapy agent.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

START FREE — 10,000 calls/day, no key needed